GI Diseases Flashcards
fatigue, nausea, anorexia, fever, arthralgia, mylagia, h/a, RUQ pain
All Hepatitis: Symptoms
jaundice, scleral icterus, coca-cola urine, hepatomegaly
All Hepatitis: Signs
very high ALT/AST, high TP+AP, bilirubin in urine, increase IgM
All Hepatits: Labs
diffuse periportal lymphocytic inflammation, hepatocellular ballooning
All Hepatitis: Biopsy
Oral-fecal, asympotomatic in children
Hepatitis A: MOI
ALT and symptoms peak in 1 month, IgM peaks 3 months post-infxn
Hep A
Nonenveloped ssRNA virus; @2wks - excreted in stool; @4wks - increased ALT, Sx begin; @8wks - resolution
Hepatitis A: Pathophysiology
Never chronic, no tx but gamma-globulin vaccine available (passive)
Hepatitis A: Treatment/Notes
Horizontal (IVDU, sex) in US
Hepatitis B: Epi/MOI
The only enveloped, partially double-stranded DNA virus; 6-8wk incubation, 20% serum sickness prodrome
Hepatitis B: Pathophysiology
Progresses to chronic in 4%, Tx and vaccine (passive + active)
Hepatitis B: Treatment/Notes
Epi: HepB coinfection/hx
Hepatitis D: Epi/MOI
Delta agent, uses HBsAg protein coat, HepB must be present
Hepatitis D: Pathophysiology
Pigs
Hepatitis E: Epi/MOI
~HepA, waterborne, endemic in Asia, N. Africa, Mexico
Hepatitis E: Pathophysiology
350M; 1M in US
Chronic Hepatitis B: Epi/MOI
Labs: increased ALT+AST >6mo, (+)HBsAg, (+)HBcAb IgG; Biopsy: Ground glass
Chronic Hepatitis B: Signs/Symptoms/Findings
Vertical transmission predominant in most parts of the world; can lead to HCC; see charts on Chronic Hepatitis B
Chronic Hepatitis B: Pathophysiology
PEG-interferon, tenofovir / entecavir to decrease HBV DNA levels; not curative
Chronic Hepatitis B: Treatment/Notes
170M; 3M in US;
Chronic Hepatitis C: Epi/MOI
Labs: increased ALT+AST >6mo, (+)anti-HCV, (+)HCV RNA; Biopsy: Portal lymphoid aggregates, interface hepatitis
Chronic Hepatitis C: Signs/Symptoms/Findings
Unlike chronic HepB, anti-HCV doesn’t kill virus; but also unlike HBV, HepC can be cured (in ~75%), since no virus in nucleus
Chronic Hepatitis C: Pathophysiology
PEG-interferon, ribavirin, (+boceprevir/telaprevir in genotype 1); SNP encoding interferon(IFN lamba 3) = 2x change in response
Chronic Hepatitis C: Treatment/Notes
Decades of alcohol use
Alcoholic Hepatitis / ASH (Alcoholic Steatohepatitis : Epi/MOI
Acute jaundice, liver failure, hepatomegaly, ascites, encephalopathy; increased AST+ALT, AST:ALT >2:1; PMNs, ballooned hepatocytes, Mallory bodies, centrilobular macrosteatosis, chicken-wire fibrosis
Alcoholic Hepatitis / ASH (Alcoholic Steatohepatitis : Signs/Symptoms/Findings
Acetaldehyde (toxic metabolite of alcohol) damages central hepatocytes, leads to production of TGs; some degree of fibrosis but generally not cirrhotic; can see portal HTN from hepatic swelling
Alcoholic Hepatitis / ASH (Alcoholic Steatohepatitis : Pathophysiology
Tx: Abstinence, banana bag, steroids (esp. if discriminant fxn >32, which = poor prognosis), pentoxifylline (anti-TNF), need 6 mo abstinence for xplant
Alcoholic Hepatitis / ASH (Alcoholic Steatohepatitis : Treatment/Notes
Metabolic syndrome, M>F, 40-60 yo
NAFL (Non-Alcoholic Fatty Liver)& NASH: Epi/MOI
Same as ASH except mixed PMNs + lymphos, AST:ALT <1; also see perivenular and sinusoidal fibrosis
NAFL (Non-Alcoholic Fatty Liver) & NASH: Signs/Symptoms/Findings
1st hit: increased TG’s, FFA; 2nd hit: oxidative stress leads to lipid peroxidation, cytokine release, damage to cell membranes + mitos
NAFL (Non-Alcoholic Fatty Liver) & NASH: Pathophysiology
Less cirrhosis risk than ASH; Tx: wt loss, exercise, glycemic/lipid control, pioglitazone, vitamin E
NAFL (Non-Alcoholic Fatty Liver)& NASH: Treatment/Notes
Rare Steatosis
Small Droplet Steatosis: Epi/MOI
Small fat vacuoles, nucleus at center
Small Droplet Steatosis: Signs/Symptoms/Findings
Severe mitochondrial injury leads to decrease beta-FA oxidation
Small Droplet Steatosis: Pathophysiology AND Treatment/Notes
Normal blood bilirubin
<17microM, 1 mg/dL
In real life, unconjugated serum bilirubin percent
96%
Lab overestimates conjugated bili by up to
30%
bilirubin level leading to jaudince
> 35 microM
conjugated hyperbilirubinemia always caused by
impaired secretion of BDG from hepatocytes OR biliary obstruction
heptocellular causes of conjugated hyperbilirubinemia
cirrhosis, acute hepatitis (drugs, viral, alcohol)
biliary obstruction causes of cinjugated hyperbilirubinemia
gallstones, tumors, primary biliary cirrhosis
Dubin-Johnson syndrome (ABCC2) & Rotor syndrome (SLCO1B1/IB3)
genetic conjugated hyperbilirubinemia
unconjugated hyperbilirubinemia: overproduction causes
hemolysis, bad erythropoesis
unconjugated hyperbilirubinemia: impaired uptake causes
fast, sepsis, drugs (probenicid)
unconjugated hyperbilirubinemia: impaired conjugation causes
inherited mutations/polymorphisms
Crigler-Najjar (UGT1 mut) & Gilbert sydrome (polymorphism)
cause impaired conjugation unconjugated hyperbilirubinemia
less H bonding in E diastereoisomers, makes unconj. Bili more water soluble
phototherapy in neonates with jaudice
metabolism produces a hepten that binds to cells, triggers T-cells and eosinophils
drug-induced hepatitis
M>F (due to .’s), N. Euros. Variable penetrance
Hemachromatosis: Epi/MOI
Bronzing diabetes, HCC, cirrhosis, cardiomyopathy; transferrin saturation (TIBC) >50% in F, >60% in M
Hemachromatosis: Signs/Symptoms/Findings
HFE mutation (C282Y +/+ or H63D/C282Y) results in decrease hepcidin, which is usually inhibitor of iron absorption, recycling, storage
Hemachromatosis: Pathophysiology
Tx: phlebotomy; liver xplant if bad; can also see iron overload due to causes other than HFE mutation. Can halt symptoms, but cannot reverse damage
Hemachromatosis: Treatment/Notes
AR, 1/30K, 2-40 yo
Wilson’s Disease: Epi/MOI
Kayser-Fleischer rings, decrease ceruloplasmin, urinary Cu high, stool low (25% direct, 50% as metallothionin),low AlkP, AST+ALT > 2.2, renal dz
Wilson’s Disease: Signs/Symptoms/Findings
ATP7B on chr17 encodes metal-transporting ATPase, mutation results in excessive copper in liver and brain
Wilson’s Disease: Pathophysiology
Chelation (penicillamine), zinc (prevents absorbtion), transplant if bad (always fatal without tx)
Wilson’s Disease: Treatment/Notes
Biopsy: (+)PAS granules; Labs: decrease alpha 1AT;Chronic hepatitis, cirrhosis
Alpha-1-Antitrypsin Deficiency: Signs/Symptoms/Findings
SERPINA ZZ, some ZS, rarely SS leads to alpha 1AT getting trapped within ER of hepatocytes, leads to fibrosis, cirrhosis, HCC
Alpha-1-Antitrypsin Deficiency: Pathophysiology
Serpina Pi null-null
no a1t, severe lung disease, no liver dz
Tx: smoking cessation, abstinence, pneumovax, alpha 1AT, manage chronic liver dz, augementum for lungs, only xplant cures liver
Alpha-1-Antitrypsin Deficiency: Treatment/Notes
F>M 4:1, dx by exclusion, biopsy
Autoimmune Hepatitis (AIH), overlap syndromes: Epi/MOI
Acute hepatitis (30%), occ fulminant, 34% asympt; increased ALT + AST, IgG, gamma-globulin ; plasma cell infiltrate + interface hepatitis
Autoimmune Hepatitis (AIH), overlap syndromes: Signs/Symptoms/Findings
97% are Type 1: anti-smooth muscle Ab (SMA) and/or ANA, age 16-30; Type 2: anti-ILKM1, affects kids 2-14yo; type III looks like one, adults 30-50
Autoimmune Hepatitis (AIH): Pathophysiology
Tx: Prednisone + azathioprine, 10yr survival 90% but 3yr relapse 90%; long-term Tx usually necessary; xplant
Autoimmune Hepatitis (AIH), overlap syndromes: Treatment/Notes
AIH + (PBC or PSC)
Overlap Syndromes: Pathophysiology
F>M, other AI diseases
Primary Biliary Cirrhosis (PBC): Epi/MOI
(+)AMA, increased AlkP and gamma-globulin, fatigue, pruritus, cirrhotic Sx, chronic cholangitis
Primary Biliary Cirrhosis (PBC): Signs/Symptoms/Findings
AMA (anti-mitochondrial Ab) vs. small intrahepatic bile ducts
Primary Biliary Cirrhosis (PBC): Pathophysiology
Tx: Ursodeoxycholic acid; cholestyramine for pruritus
Primary Biliary Cirrhosis (PBC): Treatment/Notes
M>F 3:1, 20s-30s, 80% IBD (mostly UC)
Primary Sclerosing Cholangitis (PSC): Epi/MOI
increased increased AlkPhos+TB, increased ALT+AST, gamma-globulin, (+)pANCA, ANA, SMA, (-)AMA; Onion-skin fibrosis on biopsy, Beads-on-a-string on ERCP
Primary Sclerosing Cholangitis (PSC): Signs/Symptoms/Findings
ANCA>ANA>SMA vs. both intrahepatic and extrahepatic bile ducts
Primary Sclerosing Cholangitis (PSC): Pathophysiology
Median survival 12 yrs; transplant is only way to improve; watch for colon cancer, cholangiocarcinoma, gallbladder dz, IBD, metabolic bone disorder
Primary Sclerosing Cholangitis (PSC): Treatment/Notes
Cholestasis: increased direct bili, pruritus, jaundice, xanthomas, fibrosis, ADEK deficiency, fat malabsorption, hepatocellular injury, acholic stool (grey/white)
Infectious Hepatitis, TPN-associated cholestasis, galactosemia, tyrosemia, idiopathic neonate hepatitis: Signs/Symptoms/Findings
ToRCHeS - Toxo, Rubella, CMV, HSV, Syphilis; Coxsackie; Echovirus
Infectious Hepatitis: Pathophysiology AND Treatment/Notes
Premies
TPN-Associated Cholestasis: Epi/MOI
Lipids in TPN worsens underlying dz
TPN-Associated Cholestasis: Pathophysiology
Tx: feed, cycle or stop TPN
TPN-Associated Cholestasis: Treatment/Notes
AR pediatric liver diseases
Galactosemia, Tyrosemia, PFIC, Congential Hepatic fibrosis: Epi/MOI
Galactose-1-phosphate-uridyl transferase mutation leads to fatty liver
Galactosemia: Pathophysiology
Tx: galactose/lactose-free formula
Galactosemia: Treatment/Notes
Fumaryl acetoacetate hydrolase deficiencylead to increased succinyl acetone
Tyrosinemia: Pathophysiology
Dx: urinary succinyl acetone; Tx: transplant curative
Tyrosinemia: Treatment/Notes
Jaundice in 1st week of life, fulminant in 30% (giant cell hepatitis, necrosis)
Idiopathic Neonatal Hepatitis: Pathophysiology
Also increased indirect bili; 30-40% of neonatal cholestasis;
Idiopathic Neonatal Hepatitis: Treatment/Notes
1/10K, 1wk old, acholic stools,
Biliary Atresia : Epi/MOI
Biopsy: swirly, neuron-like ductule cells with bile plugs
Dx: abd USG to r/o other causes, HIDA w/ phenobarb, increased direct bili
Biliary Atresia : Signs/Symptoms/Findings
Idiopathic proliferation of bile ductules with bile plugs leading to blockage of bile ducts; cause of 50-60% of liver transplants in kids
Biliary Atresia : Pathophysiology
Kasai hepatic porto-enterostomy to delay progression to biliary cirrhosis and transplant
Biliary Atresia : Treatment/Notes
Abdominal ultrasound shows cysts, dilation (in children)
Choledochal Cyst: Signs/Symptoms/Findings
Congenital weakness in wall of common bile ductlead to dilation, cyst
Choledochal Cyst: Pathophysiology
Resection due to malignancy potential
Choledochal Cyst: Treatment/Notes
AD, variable penet. Pediatric liver dz
Alagille Syndrome: Epi/MOI
Triangular facies, ocular / CV / vertebral anomalies, decrease growth, pruritus, xanthomas
Alagille Syndrome: Signs/Symptoms/Findings
JAG1 mutation results in dysfunctional Notch signaling, malformation and paucity of intrahepatic bile ducts, arteriohepatic dysplasia
Alagille Syndrome: Pathophysiology
Prolonged survival good but defective spermatogenesis
Alagille Syndrome: Treatment/Notes
increased AlkPhos, pruritus, normal GGT; biliary paucity, giant cells
Progressive Familial Intrahepatic Cholestasis (PFIC): Signs/Symptoms/Findings
Defect in ATP8B1 (type 1: ATPase) or BSEP (2: salt pump) leads to bile transport problems
Progressive Familial Intrahepatic Cholestasis (PFIC): Pathophysiology
External biliary diversion, esp. in type 1; transplant
Progressive Familial Intrahepatic Cholestasis (PFIC): Treatment/Notes
Abd pain, cholangitis, varices; ductular cells, no cirrhosis (in children)
Congenital Hepatic Fibrosis: Signs/Symptoms/Findings
Malformation of embryonic ductal plate leads to fibrosis, ARPKD
Congenital Hepatic Fibrosis: Pathophysiology
Comorbid with Caroli’s
Congenital Hepatic Fibrosis: Treatment/Notes
75% M
Caroli’s Disease: Epi/MOI
Abd pain, hepatomegaly, Gm- sepsis, CBD normal
Caroli’s Disease: Signs/Symptoms/Findings
Multiple saccular dilatations of intrahepatic ducts (~choledochal cyst)
Caroli’s Disease: Pathophysiology
Stenting, Abx, pain meds, transplant curative
Caroli’s Disease: Treatment/Notes
CT: lumpy-bumpy, enlarged liver; Biopsy: collagen; increased TB (Tx: see PBC), increased PT/INR
Cirrhosis: Epi/MOI AND Signs/Symptoms/Findings
Chronic inflammationlead to fibrosis from stellate cells, regenerative nodules, distortion of liver parenchyma; etiologies = HepB/C, EtOH, autoimmune, congenital, toxins
Cirrhosis: Pathophysiology
Pro-oncogenic environment (1-5% / yr progress to cancer); prognosis: compensated 8.9 yrs, decompensated 1.6 yrs
Cirrhosis: Treatment/Notes
Other sequelae include hepatic hydrothorax (Tx: ~ascites), hyponatremia (Tx: decrease fluids, vaptans), hepatoencephalopathy, varices, portopulmonary syndrome
Portal Hypertension: Epi/MOI AND Signs/Symptoms/Findings
Portal pressure increased >7mm Hg (>10 is “significant”) from increased outflow resistance (fibrosis or vasoconstriction) + increased inflow; Tx: beta blockers, octreotide
Portal Hypertension: Pathophysiology AND Treatment/Notes
SAAG >1.1, nl glucose, low LDH, low protein+amylase
Ascites: Signs/Symptoms/Findings
> 10mmHglead to fluid in peritoneal cavity from lymphatic backflow
Ascites: Pathophysiology
Tx: Low Na+ diet, diuretics, LVP, TIPS
Ascites: Treatment/Notes
increased WBC (>500, or >250 with more than half polys), (+)culture (klebsiella, e.coli, entercoccus, pneumococcus)
Spontaneous Bacterial Peritonitis (SBP): Signs/Symptoms/Findings
Ascites fluid infected by bacteria or fungi w/o gut perforation
Spontaneous Bacterial Peritonitis (SBP): Pathophysiology
Tx: 3G cephalosporin x 5d
Spontaneous Bacterial Peritonitis (SBP): Treatment/Notes
Serum Cr >1.5, despite volume expansion, d/c diuretics
Hepatorenal Syndrome: Signs/Symptoms/Findings
Renal insufficiency with cirrhosis and ascites; Type 1 worse than Type 2
Hepatorenal Syndrome: Pathophysiology
Tx: Albumin, midodrine, octreotide, TIPS, liver xplant
Hepatorenal Syndrome: Treatment/Notes
Platypnea-orthodeoxia, clubbing, cyanosis
Hepatopulmonary Syndrome: Signs/Symptoms/Findings
V-Q mismatch from vasodilation in lung due to NO from portal HTN
Hepatopulmonary Syndrome: Pathophysiology
Tx: O2, liver transplant
Hepatopulmonary Syndrome: Treatment/Notes
Gross: “Nutmeg liver” Biopsy: congestion near central vein
Centrilobular Congestion: Signs/Symptoms/Findings
Right-sided heart failure (or biventricular heart failure)
Centrilobular Congestion: Pathophysiology AND Treatment/Notes
Biopsy: necrosis near central vein
Centrilobular Necrosis: Signs/Symptoms/Findings
Left-sided heart failure
Centrilobular Necrosis: Pathophysiology
Ascites & increased coag state
Budd-Chiari Syndrome: Signs/Symptoms/Findings
Liver (cont’d)
Budd-Chiari Syndrome: Cat
Thrombi/tumor invade hepatic vein/IVC; liver blocked, congested
Budd-Chiari Syndrome: Pathophysiology
50% due to Tylenol
Acute Liver Failure (ALF): Epi/MOI
Acute, change MS, coagulopathy (increased INR), no cirrhosis; coagulative necrosis
Acute Liver Failure (ALF): Signs/Symptoms/Findings
Drugs, viruses, toxins, metabolic dz, ischemia, etc. leads to liver damage; can lead to encephalopathy, infection, cerebral edema, renal failure, SIRS
Acute Liver Failure (ALF): Pathophysiology
ICU, IV N-acetylcysteine if acetaminophen, early liver transplantation (other organs usually recover)
Acute Liver Failure (ALF): Treatment/Notes
28% Tylenol, 52% indeterminate (probably viral)
Pediatric Acute Liver Failure: Epi/MOI AND Signs/Symptoms/Findings
Acetaminophen better prognosis than viral/indeterminant
Pediatric Acute Liver Failure: Pathophysiology
OLT (King’s college criteria)
Pediatric Acute Liver Failure: Treatment/Notes
Asterixis, stupor, coma, change LOC
Hepatic Encephalopathy: Signs/Symptoms/Findings
Gut neurotoxin (e.g. NH3) bypass liver due to portal-systemic shunt
Hepatic Encephalopathy: Pathophysiology AND Treatment/Notes
1M die / yr
Hepatocellular Carcinoma: Epi/MOI
Screen with liver USG q6mo in at-risk pts, vaccinate for HBV
Hepatocellular Carcinoma: Signs/Symptoms/Findings
Screen ALF pts every 6 mos
for Hepatocellular Carcinoma
Chemo, RF ablation
Hepatocellular Carcinoma: Treatment/Notes
hepatic failure + iron deposition
gestational alloimmune liver disease
complement cascade activates, intrauterine onset. Anti-human C5B9 complex
gestational alloimmune liver disease
IVIg, exchange transfusion, OLT
gestational alloimmune liver disease
PT prolongs within
one day of liver dysfunction
marked ALT/AST elevation
hepatocellular
marked AlkP, TB elevation
cholestatic
marked AlkP only
infiltrative
normal albumin
3.5-5.3
normal AST
six-40
normal Alk-P
30-120
normal TB
0.1-1
normal direct B
0.1-0.4
normal GGT
0-42
normal INR (PT ratio)
1
dx biliary obstruction
MRCP (costly)
test to access cirrhosis
liver-spleen scan (medium)
will not evaluate liver function, can’t detect fibrosis, rarely reveals etiology
CT, MRI/MRCP
mild elevation
<5x normal
severe elevation
> 15x normal
decreases UGT1 activity, increased bili production, bad erthropoesis and decreased RBC survival
why babies be jaundiced
female, advanced age, DM, obese, chronic viral disease, alcohol, decreased renal fxn, nutritional deprivation
factors associated with drug-related liver damage
acetominophen, after P450, produced
toxic NAPQ1
tylenol and beer both
deplete glutathione, leading to mercapturic acid conjugates and mitochondrial dysfunction
picornaviridal hepatovirus
hep A
hepandaviridae
hepB
flaviveridal hepacivirus
hep C
unclassified viroid, delta virus
hep D
unclassified, toga- and alphavirus-like
hep E
mono, lymphadenopathy, splenomegaly and hepatitis
EBV
immunocompromised with hepatitis
CMV?
HBsAg
acute or chronic hep B
Anti-HBc IgM
acute hep B